Merck (MRK) Says KEYTRUDA More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic NSCLC with High Levels of
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of updated overall survival ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
